According to a recent LinkedIn post from Draig Therapeutics, the company is scheduled to present new data from its first in human Phase 1 trial of DT-101 at the American Society of Clinical Psychopharmacology Annual Meeting in Miami. The post indicates that the oral presentation and two posters will focus on favorable tolerability findings and functional biomarker data for DT-101, described as a novel AMPA receptor positive allosteric modulator.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post specifies an oral presentation on Tuesday, May 26, 2026, and poster sessions on Thursday, May 28, 2026, suggesting multiple opportunities for scientific visibility among clinical psychopharmacology specialists. For investors, the emphasis on tolerability and biomarker readouts at this stage may be an early indicator of de risked safety characteristics, which can be important for future trial progression and partnering interest.
The post also invites interested parties to contact the team, implying an effort to engage clinicians, researchers, and potentially business development stakeholders during the conference. If the data resonate positively with the scientific audience, this exposure could strengthen Draig Therapeutics’ positioning in central nervous system drug development and potentially support future financing or collaboration discussions around DT-101 and its AMPA modulation platform.